SKT-045

Human Gastrin-17 CLIA Kit

Description

Human Gastrin-17 CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human Gastrin-17(G-17) concentration in serum.

For in-vitro diagnostics purposes only.

Background


The Human Gastrin-17 CLIA Kit is designed, developed, and produced for the quantitative measurement of human G-17 level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of G-17.
​​​​​​​Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with streptavidin coated magnetic particles, acridinium ester conjugated G-17 monoclonal antibody and biotinylated anti-G-17 polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immune-complex in the form of “magnetic particles– biotin G-17 antibody–G-17–acridinium ester G-17 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are proportional to the concentration of a G-17 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum G-17 concentration.

Specifications

Catalog no. SKT-045
Target Gastrin-17(G-17)
Species Human
Method Sandwich CLIA
Tests Per Kit 100 tests
Detection Flash AE Chemiluminescence
Sensitivity / LLOD ≤0.200 pmol/L
Dynamic Range ***
Total Incubation Time 10 Minutes
Sample Type Serum
Sample Volume 50 µL
Storage Temperature 2-8 °C

Selected Literature


1. Sun.L, Tu.H, et al. A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population.Scand J Gastroenterol, 2014, 49(10): 1164-1172.
2. Cavallaro G, Nouvenne A, et al. Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastroesophageal reflux disease (GERD) independently of H. pylori status. Gastroenterol, 2006, 130(4): A-168
​​​​​​​
For in-vitro diagnostic use.